Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Blood (2025) 146 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2025-7624

Published: 2025

Journal Articles

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Andrea Rivero, Monica Molina, Laura Julià, Víctor Navarro Garces, Juan Correa, Helena Brillembourg, Eduardo Aguilar-Meseguer, Carmen Rodríguez-Miñón, Isabel Hernández, Amanda Perez, Nuria Martinez-Cibrian, Valentin Ortiz-Maldonado, Nil Albiol, Aina Oliver-Caldes, Julio Delgado Gonzalez, Eva Gine, Pablo Mozas, Armando Lopez-Guillermo, Laura Magnano

Blood (2025) 146 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2025-5386

Published: 2025

Journal Articles

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 3983.

https://doi.org/10.1182/blood-2025-3983

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Blood (2025) 145 (22): 2599–2613.

https://doi.org/10.1182/blood.2024025440

Published: 2025

Includes: Supplemental data

Journal Articles

Dual biological role and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia

Blood (2025) 145 (21): 2473–2487.

https://doi.org/10.1182/blood.2024025396

Published: 2025

Includes: Supplemental data

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2024-205717

Published: 2024

Journal Articles

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 112.

https://doi.org/10.1182/blood-2024-201946

Published: 2024

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Valentin Ortiz-Maldonado, Nuria Martínez-Cibrián, Leticia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, Margaux Faes, Marte C. Liefaard, Margot J. Pont, Maike Spoon, Kirsten Van Hoorde, Anna D. D. van Muyden, Julio Delgado, Natalia Tovar

Blood (2024) 144 (Supplement 1): 3452.

https://doi.org/10.1182/blood-2024-207546

Published: 2024

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Blood (2024) 144 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2024-206082

Published: 2024

Journal Articles

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Blood (2024) 144 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2024-206032

Published: 2024

Journal Articles

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 965.

https://doi.org/10.1182/blood-2024-205669

Published: 2024

Journal Articles

CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

Ane Altuna Mongelos, Lorena Perez Amill, Maria Val-Casals, Sergio Peña, Mercedes Armand-Ugon, Jose Ramón Álamo Moreno, Juan Gonzalo Correa, Alvaro Urbano-Ispizua, Julio Delgado, Claudio Santos, Manel Juan, Nela Klein-Gonzalez

Blood (2024) 144 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2024-207309

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Blood (2023) 142 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2023-182896

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Dual biological role and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only